Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I/II Study of simmitecan hydrochloride plus DP303c in HER2-low recurrent/metastatic breast cancer
CTR20243138Phase 2Active
- Sponsor
- Shanghai Institute of Materia Medica
- Start
- Aug 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of simmitecan, DP303c in breast cancer, sponsored by Shanghai Institute of Materia Medica. Started Aug 2024; status: active.
02
Drugs
simmitecanDP303c
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20243138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243138.